Psychopharmacology and Psychiatry Updates

Chris Aiken, psychiatrist and editor who reviews pharmacogenetic literature, breaks down SERT (SLC6A4) testing and its link to SSRI response. He explains alleles, theoretical mechanisms, and why pharmacodynamic predictions are unreliable. He reviews meta-analyses, population differences, stress-related claims, and offers practical advice on interpreting test results in clinic.

Paul Zarkowski, a consultation-liaison psychiatrist and academic, reviews a meta-analysis on SSRI plus anticoagulant bleeding risk. He outlines the pooled increased hazard and differences with direct oral anticoagulants. Age, sex, and baseline anticoagulant risk are discussed. Mechanisms of SSRI-related platelet effects and safer antidepressant alternatives are highlighted.

Chris Aiken, psychiatrist and editor known for clear analysis of psych med evidence. He unpacks why pharmacogenetic testing looks promising but flops in blinded trials. He contrasts single-gene actionable tests with broad panels. He calls out bias in early studies, statistical pitfalls, lab inconsistencies, and offers practical testing recommendations.

Kristin Raj, psychiatrist and clinical educator specializing in psychopharmacology and mood disorders. She discusses lurasidone at low doses for bipolar I depression with comorbid anxiety. Short doses (20–60 mg/day) may improve both mood and anxiety and show favorable metabolic and tolerability profiles. Practical dosing advice and reasons why higher doses might be less helpful are explored.

Oliver Freudenreich, M.D., a psychiatrist specializing in clinical psychopharmacology, discusses the groundbreaking potential of GLP-1 agonists in combating weight gain from antipsychotics. He explores the prevalence and associated health risks of this issue, noting the shortcomings of traditional weight management strategies. Delving into mechanisms, he highlights GLP-1's effects on satiety and glucose metabolism. With insights on clinical applications, he emphasizes the urgency of integrating these treatments while continuing essential research.

Dr. Chris Aiken, a psychiatrist and educator, dives deep into pharmacogenetics-guided dosing. He reveals how understanding whether patients are poor or rapid metabolizers can change treatment outcomes dramatically. Aiken emphasizes tailored dosing strategies: for poor metabolizers, he suggests starting low and going slow, while for rapid metabolizers, targeting higher doses works best. He also discusses the importance of monitoring clinical response and serum levels, highlighting a personalized approach to psychiatric care. A must-listen for mental health professionals!

Dr. Oliver Freudenreich, a leading psychiatrist in psychopharmacology, shares insights from the newly released INTEGRATE guidelines for schizophrenia treatment. He discusses the importance of establishing a universal treatment algorithm to enhance care standards. Key points include the early use of long-acting injectables and clozapine for treatment-resistant patients, as well as recommendations for first-episode antipsychotics. Freudenreich emphasizes shared decision-making and integrating medical management for optimal patient outcomes.

Dr. Chris Aiken, a prominent psychiatrist and editor-in-chief known for his expertise in psychopharmacology, dives into the world of pharmacogenetics. He discusses essential genetic tests that matter in psychiatric practice, cutting through marketing misconceptions. Learn about vital metabolic tests like CYP2D6, CYP3A4, and the implications of HLA-B*1502 for drug safety. He explains how understanding genetic variability can prevent severe side effects and improve patient outcomes, highlighting real-world applications and FDA requirements.

In this discussion, Dr. Paul Zarkowski, a psychiatrist and faculty contributor, dives into his comparative study on lithium versus quetiapine for treatment-resistant depression. He reveals real-world data on efficacy and side effects that spans an entire year. The conversation explores short-term remission rates and how these treatments fare against STAR*D findings. Zarkowski highlights the implications of side effects and the importance of individualized treatment choices, providing valuable insights for clinicians navigating difficult cases.

Psychiatrist Lauren Osborne, an expert in perinatal psychopharmacology, dives into the complex interplay of postpartum psychosis and bipolar disorder. She shares insights on the use of mood stabilizers, particularly lithium, in breastfeeding mothers. Osborne emphasizes that sleep disruption often influences breastfeeding choices more than drug exposure. She also outlines the relative risks of medications like lamotrigine and lithium during lactation, advocating for early lithium treatment while managing risks for both mother and infant.